Adverse effects of the herd immunity or when childhood vaccination becomes deleterious for the epidemiology of infectious diseases in adults;Les effets indésirables de l'immunité de « groupe » ou quand la vaccination infantile devient délétère pour l'épidémiologie infectieuse de l'adulte

Geriatrie et Psychologie Neuropsychiatrie du Vieillissement

Volumn 9, Issue 1, 2011, Pages 11-19

  Lang, Pierre Olivier ^a,b  

^a Hopital de Geriatrie   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Herd immunity; Old individuals; Vaccination; Vaccine programme

Indexed keywords

23 VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; 23-VALENT PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ADULT; AGE; AGED; ARTICLE; CHILD; COMMUNICABLE DISEASE; EPIDEMIC; FRANCE; HERD IMMUNITY; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; METHODOLOGY; MIDDLE AGED; STREPTOCOCCUS PNEUMONIA; VACCINATION;

ADULT; AGE FACTORS; AGED; CHILD; COMMUNICABLE DISEASES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; EPIDEMICS; FRANCE; HUMANS; IMMUNITY, HERD; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; VACCINATION;

EID: 79953046182     PISSN: 21158789     EISSN: 21157863     Source Type: Journal    
DOI: 10.1684/pnv.2011.0260     Document Type: Article

References (55)

1. World Health Organization (WHO). The centralized information system for infectious diseases (CISID). Genève, Suisse : WHO, 2009.
2. Poland GA, Jacobson RM, Ovsyannikova IG. Trends affecting the future of vaccine development and delivery: the role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics. Vaccine 2009 ; 27 : 3240-4.
3. Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis 2002 ; 2 : 659-66. (Pubitemid 35265061)
4. Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clin Infect Dis 2000 ; 30 : 931-3. (Pubitemid 32250334)
5. Michel JP, Lang PO. Promoting life course vaccination. Rejuvenation Res 2011 ; Jan 5 (Epub ahead of print).
6. Lang PO, Michel JP. La vaccination : le programme de toute une vie. Rev Med Suisse 2010 ; 6 : 2118-24.
7. Lang PO, Govind S, Mitchell WA, Siegrist CA, Aspinall R. Vaccine effectiveness in older individuals: What has been learned from the influenza-vaccine experience. Ageing Res Rev 2010 ; Oct 1 (Epub ahead of print).
8. Lang PO, Mitchell WA, Lapenna A, Pitts D, Aspinall R. Immunological pathogenesis of main age-related diseases and frailty: role of immunosenescence. Eur Geriatr Med 2010 ; 1 : 112-21.
9. Lang PO, Govind S, Mitchell WA, Kenny N, Lapenna A, Pitts D, et al. Influenza vaccine effectiveness in aged individuals: the role played by cell-mediated immunity. Eur Geriatr Med 2010 ; 1 : 233-8.
10. Baeyens JPLP, Michel JP. Willingness to vaccinate and to be vaccinated in adults. Aging Clin Exp Res 2009 ; 21 : 244-9.
11. Evans MR, Prout H, Prior L, Trapper-Jones LM, Butler CC. A qualitative study of lay beliefs about influenza immunization in older people. Br J Gen Pract 2007 ; 57 : 352-8. (Pubitemid 46766378)
12. Blank PR, Schwenkglenks M, Szucs TD. Vaccination coverage rates in eleven European countries during two consecutive influenza seasons. J Infect Dis 2009 ; 58 : 446-58.
13. Michel JP, Chidiac C, Grubeck-Loebenstein B, Johnson RW, Lambert PH, Maggi S, et al. Coalition of advocates to vaccinate of Western European citizens aged 60 years and older. Aging Clin Exp Res 2009 ; 21 : 254-7.
14. Michel JP. Updated vaccine guidelines for aging and aged citizens of Europe. Expert Rev Vaccines 2010 ; 9 : 7-10.
15. Reichert TA, Sagaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001 ; 344 : 889-96. (Pubitemid 32224397)
16. Carman WF, Elder AG, Wallace LA. Effects of influenza vaccination of health care workers on mortality of elderly people in long-term care: a randomized controlled trial. Lancet 2000 ; 355 : 93-7. (Pubitemid 30068552)
17. Centers for Disease Control Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003.MMWRMorb Mortal Wkly Rep 2005 ; 54 : 893-7.
18. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006 ; 354 : 1455-63.
19. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003 ; 348 : 1737-46.
20. John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol 2000 ; 16 : 601-6.
21. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Lancet 1990 ; 335 : 641-5. (Pubitemid 20092661)
22. Anderson RM. The concept of herd immunity and the design of community-based immunization programmes. Vaccine 1992 ; 10 : 928- 35.
23. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993 ; 15 : 265-302. (Pubitemid 24072630)
24. Dowdle WR, Millar JD, Schonberger LB, Ennis FA, LaMontagne JR. Influenza immunization policies and practices in Japan. J Infect Dis 1980 ; 141 : 258-64. (Pubitemid 10100306)
25. Hirota Y, Fedson DS, Kaji M. Japan lagging in influenza jabs. Nature 1996 ; 380 : 18.
26. Centers for Disease Control Prevention (CDC). Recommendation of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2004 ; 53(RR-06) : 1-40.
27. Black S, Shinefield H, Fireman B, et al. Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000 ; 19 : 187-95. (Pubitemid 30167436)
28. Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, et al. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007 ; 26 : 771-7. (Pubitemid 47329845)
29. Office fédérale de la santé publique (OFSP) disponible sur internet à http://www.bag.admin.ch. Recommandations pour la vaccination contre les pneumocoques chez les enfants de moins de 5 ans. Disponible sur Internet: http://wwwbagadminch.
30. Halperin SA. Pertussis - a disease and vaccine for all ages. N Engl J Med 2005 ; 353 : 1615-7. (Pubitemid 41434642)
31. Bonmarin I, Santa-Olalla P, Lévy-Bruhl D. Modeling the impact of vaccination on the epidemiology of varicella zoster virus. Rev Epidemiol Sante Publique 2008 ; 56 : 323-31.
32. Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA. Risk of herpes zoster in adults immunized with varicella vaccine. J Infect Dis 2008 ; 197(suppl. 2) : S196-9. (Pubitemid 351590171)
33. Rota MC, D'Ancona F, Massari M, Mandolini D, Giammanco A, Carbonari P, et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 2005 ; 23 : 5299-305. (Pubitemid 41579299)
34. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003 ; 290 : 2968-75. (Pubitemid 37505529)
35. van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, et al. Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J Clin Microbiol 2005 ; 43 : 2837-43. (Pubitemid 40827962)
36. Güriş D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999 ; 28 : 1230-7. (Pubitemid 29272795)
37. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005 ; 24 : 761-5. (Pubitemid 41324882)
38. Diana A, Ninet B, Siegrist CA, Gervaix A, Rohner P. La coqueluche circule encore. D'un récit d'une mini-épidémie à une mise au point. Forum Med Suisse 2003 ; 34 : 786-9.
39. Hviid A, Stellfeld M, Wohlfahrt J, Andersen PH, Melbye M. The impact of pre-school booster vaccination of 4-6-year-old children on pertussis in 0-1-year-old children. Vaccine 2006 ; 24 : 1401-7. (Pubitemid 43222050)
40. Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs 2005 ; 65 : 1367-89. (Pubitemid 41043892)
41. Lang PO, Belmin J, Michel JP. Zona des sujets âgés. Press Med 2009 ; 38 : 571-83.
42. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005 ; 352 : 2271-84.
43. Kimberlin DW, Whitley RJ. Varicella zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007 ; 356 : 1338-43. (Pubitemid 46513299)
44. Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002 ; 44 : 211-9. (Pubitemid 36104786)
45. Proesmans MJ. Pneumococcal vaccination: time to move on? Eur J Pediatr 2010 ; 169 : 1435-7.
46. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO, et al. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr Infect Dis J 2006 ; 25 : 250-4. (Pubitemid 43379067)
47. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to nonpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007 ; 196 : 1346-54. (Pubitemid 351412007)
48. Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, Rasko D, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J 2007 ; 26 : 461-7.
49. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B, et al. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005 ; 192 : 1988-95. (Pubitemid 41681898)
50. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007 ; 26 : 468-72. (Pubitemid 46847304)
51. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007 ; 297 : 1784-92. (Pubitemid 46658647)
52. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, Mc Gowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin Infect Dis 2006 ; 42 : 907-14.
53. Impact de la vaccination par le vaccin antipneumococcique conjugué heptavalent sur l'incidence des infections invasives à pneumocoques en France. Analyse des données de 2008 (accessed at http:// www.invs.sante.fr/presse/2010/le-point-sur/vaccination-pneumo-050710/index.html) .
54. Moore MR, Gertz Jr. RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008 ; 197 : 1016-27. (Pubitemid 351590031)
55. Balmer P, Borrow R, Arkwright PD. The 23-valent pneumococcal polysaccharide vaccine does not provide additional serotype antibody protection in children who have been primed with two doses of heptavalent pneumococcal conjugate vaccine. Vaccine 2007 ; 25 : 6321-5. (Pubitemid 47090235)